52.17USD+2.15%Mkt Cap: 142.87M USDP/E: —Last update: 2026-05-26
Spruce Biosciences, Inc. is a biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders. The company develops TA-ERT, a fusion protein comprised of recombinant human a…
Industry Peers
Biotechnology110.61BUSDP/E 25.8
106.49BDKKP/E 20.5
66.47BUSDP/E 15.5
46.51BEURP/E 30.5
43.17BEURP/E 35.9
39.41BUSDP/E 74.0
32.84BUSD—
31.18BSEKP/E 46.1
Indicators:|
Key Statistics
Company
Market Cap142.87M USD
Enterprise Value97.76M USD
Revenue (TTM)—
Gross Profit-13.62M USD
Net Income (TTM)-38.97M USD
Revenue/Share—
Last Price52.17 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees8
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)28.49
PEG—
EV/EBITDA-3.78
EV/Revenue—
P/S—
P/B1.70
EPS (TTM)-35.82
EPS (Forward)1.85
52W Range
7.0005% of range838.13
52W High838.13 USD
52W Low7.000 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-91.65%
ROA-73.49%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-33.33M USD
CapEx (TTM)—
FCF Margin—
FCF Yield-9.22%
Net Debt-47.28M USD
Net Debt/EBITDA1.83
Balance Sheet
Debt/Equity0.02
Current Ratio4.67
Quick Ratio4.59
Book Value/Sh30.99 USD
Cash/Share19.65 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:75
Split DateAug 7, 2025
Analyst Consensus
Rating1.2 (Strong Buy)
Target (Mean)178.60 USD
Target Range120.00 USD – 283.00 USD
# Analysts5
Ownership
Shares Out.2.75M
Float2.65M
Insiders3.51%
Institutions31.05%
Short Interest
Short Ratio2.2d
Short % Float7.71%
Short % Out.7.63%
Shares Short206.11K
Short (prev mo.)170.81K
Technical
SMA 5060.20 (-13.3%)
SMA 20067.75 (-23.0%)
Beta—
S&P 52W Chg28.31%
Avg Vol (30d)77.78K
Avg Vol (10d)50.96K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—